Related Experiment Video
Updated: May 2, 2026

Recapitulating Suckling-to-Weaning Transition In Vitro using Fetal Intestinal Organoids
Published on: November 15, 2019
Human milk oligosaccharides shape small intestinal microbiota and epithelial transcriptional profile during early
Zhongxin Li1,2, Yuxi Shen1,2, Wen Wang1,2
1School of Food Science and Engineering, Overseas Expertise Introduction Center for Discipline Innovation of Food Nutrition and Human Health, South China University of Technology, Guangzhou 510640, China. zhangb@scut.edu.cn.
Human milk oligosaccharides (HMOs) are important mediators of infant colonic microbiota and host immunity, yet their region-specific effects on the small intestine remain poorly characterized. To address this, this study established an intervention model using C57BL/6J neonatal mice, in which two HMOs, namely 2'-fucosyllactose (2'FL) and lacto-N-neotetraose (LNnT), were administered daily by oral gavage from postnatal day 7 to day 28. The results showed that both HMOs enhanced systemic anti-inflammatory capacity without affecting pup growth performance. Subsequently, multi-omics analysis of the small intestine in pups revealed that 2'FL activated innate immune pathways and upregulated the expression of genes related to immunomodulation, inflammation, and intestinal barrier function, while also reducing potentially harmful bacteria (e.g., Streptococcus) and enhancing beneficial bacteria (e.g., Ligilactobacillus), with concurrent elevation of anti-inflammatory metabolites such as glycoursodeoxycholic acid and sebacic acid. Interestingly, LNnT activated adaptive immune pathways and elevated the expression of genes involved in immune system development and differentiation, B-cell and T-cell lineage specification, as well as immunoregulation, while reducing harmful bacteria (e.g., Desulfovibrio) and enhancing beneficial bacteria (e.g., Lachnoclostridium), along with increased immunomodulatory metabolites such as tricin and baicalein. Correlation network analysis revealed HMO-specific small intestinal "microbiota-metabolite-immune" axes, wherein microbial changes were strongly associated with metabolite profiles, which in turn correlated with the expression of small intestinal immune-related genes as well as serum inflammatory cytokines. This study demonstrates that HMOs can modulate the small intestinal microbiota and epithelial transcription in a structure-specific manner in pups.
Human milk oligosaccharides (HMOs) are important mediators of infant colonic microbiota and host immunity, yet their region-specific effects on the small intestine remain poorly characterized. To address this, this study established an intervention model using C57BL/6J neonatal mice, in which two HMOs, namely 2'-fucosyllactose (2'FL) and lacto-N-neotetraose (LNnT), were administered daily by oral gavage from postnatal day 7 to day 28. The results showed that both HMOs enhanced systemic anti-inflammatory capacity without affecting pup growth performance. Subsequently, multi-omics analysis of the small intestine in pups revealed that 2'FL activated innate immune pathways and upregulated the expression of genes related to immunomodulation, inflammation, and intestinal barrier function, while also reducing potentially harmful bacteria (e.g., Streptococcus) and enhancing beneficial bacteria (e.g., Ligilactobacillus), with concurrent elevation of anti-inflammatory metabolites such as glycoursodeoxycholic acid and sebacic acid. Interestingly, LNnT activated adaptive immune pathways and elevated the expression of genes involved in immune system development and differentiation, B-cell and T-cell lineage specification, as well as immunoregulation, while reducing harmful bacteria (e.g., Desulfovibrio) and enhancing beneficial bacteria (e.g., Lachnoclostridium), along with increased immunomodulatory metabolites such as tricin and baicalein. Correlation network analysis revealed HMO-specific small intestinal "microbiota-metabolite-immune" axes, wherein microbial changes were strongly associated with metabolite profiles, which in turn correlated with the expression of small intestinal immune-related genes as well as serum inflammatory cytokines. This study demonstrates that HMOs can modulate the small intestinal microbiota and epithelial transcription in a structure-specific manner in pups.
Related Concept Videos
Development of Human Microbiota
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Development of the Oral Microbiota
Microbiota of the Stomach and Small Intestine
Introduction to the Human Microbiota
Microbiota of the Large Intestine

